DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Akten is a drug marketed by Akorn and is included in one NDA. There is one patent protecting this drug.
This drug has two patent family members in two countries.
The generic ingredient in AKTEN is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.
A generic version of AKTEN was approved as lidocaine hydrochloride by WOCKHARDT BIO AG on November 18th, 1982.
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Akorn||AKTEN||lidocaine hydrochloride||GEL;OPHTHALMIC||022221-001||Oct 7, 2008||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|